FINHUB Insights

LLY · Q1 FY26 · Mar 31, 2026

Eli Lilly Q1 FY26: where the revenue came from and where it went

Eli Lilly Q1 FY26: revenue $19.8B (+56% year over year). Net profit $7.4B. Largest cohort Mounjaro $8.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
Apr 30, 2026 10-Q
Sankey diagram of Eli Lilly's income statement for Q1 FY26: revenue of $19.8 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$19.8B +56% year over year
Gross profit$16.2B 82% margin
Operating profit$8.9B 45% margin
Net profit$7.4B 37% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 19.8 100% +56%
Mounjaro 8.7 44% +125%
Zepbound 4.2 21% +80%
Other 1.8 9%
Verzenio 1.3 7% +12%
Jardiance 1.1 6% +10%
Other Oncology 1 5% +22%
Trulicity 0.9 5% −16%
Other Cardiometabolic Health 0.9 5% −4%
Cost of revenue−3.618%
Gross profit16.282% margin−1pp
SG&A−2.915%−5pp
Other−4.422%+0pp
Operating profit8.945% margin+16pp
Tax−1.4
Interest & other costs−0.1
Net profit7.437%+16pp
Filing on EDGAR More quarters of LLY

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters